Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 10, 2007

Innovive Gains European Rights to TMRC’s Oncology Candidate

  • Innovive Pharmaceuticals acquired exclusive rights from TMRC to develop and commercialize Tamibarotene in Europe. In December 2006, the company gained the North American rights to the drug.

    Tamibarotene, a synthetic retinoid drug candidate, will be evaluated in a Phase II pivotal trial in patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with all-trans retinoic acid and arsenic trioxide, Innovive reports.

    The terms of the agreement between Innovive and TMRC includes an option to license the use of Tamibarotene in other oncology disease areas including multiple myeloma, myelodysplastic syndromes, and solid tumors, except hepatocellular carcinoma.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »